Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy

Immunotherapy. 2024;16(13):859-868. doi: 10.1080/1750743X.2024.2377953. Epub 2024 Aug 6.

Abstract

Aim: To investigate the different impact of each component of lipid profile in advanced cancer patients treated with immune checkpoints inhibitors (ICIs) according to neutrophil-to-lymphocyte ratio (NLR) value.Methods: We retrospectively collected total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDL), high-density lipoproteins (HDL).Results: 407 patients were enrolled. In NLR <4 subgroup, TGs <150 mg/dl led to longer PFS (p = 0.01) and OS (p = 0.02) compared with TGs ≥150 mg/dl; LDL <100 mg/dl led to longer PFS (p = 0.004) and OS (p = 0.007) compared with LDL ≥100 mg/dl. In NLR ≥4 subgroup, TC >200 mg/dl led to longer PFS (p = 0.008) and OS (p = 0.004) compared with TC <200 mg/dl.Conclusion: We showed a distinct prognostic impact of lipid profile according to NLR.

Keywords: cholesterol; immunotherapy; lipid metabolism; neutrophil-to-lymphocyte ratio; systemic inflammation.

Plain language summary

[Box: see text].

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy* / methods
  • Lipids* / blood
  • Lymphocytes* / immunology
  • Male
  • Middle Aged
  • Neoplasms* / blood
  • Neoplasms* / immunology
  • Neoplasms* / therapy
  • Neutrophils* / immunology
  • Prognosis
  • Retrospective Studies

Substances

  • Lipids
  • Immune Checkpoint Inhibitors